Wesley Self

From left, Sean Collins, MD, MSc, Wesley Self, MD, MPH, Jessica Collins, program director, Vanderbilt Coordinating Center, and Matt Shotwell, PhD, play key roles in a now-international clinical trial platform that is investigating therapies aimed at reducing complications in patients hospitalized with COVID-19.
January 5, 2023

VUMC-led COVID-19 clinical trial platform goes international

The ACTIV-4 Host Tissue clinical trial platform, which is designed to investigate therapies targeting the host tissue response to COVID-19 to mitigate lung injury, is now being expanded internationally.

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.
December 16, 2022

Bivalent booster vaccine effective in preventing COVID-19 hospitalization in older adults

The new bivalent mRNA COVID-19 booster vaccines that began being used in September are beneficial in preventing COVID-19-associated hospitalization in persons 65 and over.

Gordon Bernard, MD, is stepping down from his institutional leadership roles next summer to focus on his research interests.
December 16, 2022

VUMC Announces VICTR Leadership Transition

September 22, 2022

Self named co-principal investigator of Vanderbilt’s Clinical and Translational Science Award

Wesley Self, MD, MPH, a physician-scientist at Vanderbilt University Medical Center, has been named co-principal investigator (co-PI) of Vanderbilt’s Clinical and Translational Science Award (CTSA).  

July 7, 2022

Convalescent plasma doesn’t help severely ill COVID patients: study

A Vanderbilt clinical trial shows that convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover

April 13, 2022

Additional COVID vaccine helps protect transplant patients

Additional booster doses of vaccine against COVID-19 are particularly important for those who are immunosuppressed, namely those who have had solid organ transplants, a new study shows.